Cartesian Therapeutics (RNAC) Total Debt (2015 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly Total Debt of $24.0 million for Q2 2023, down 7.32% year-over-year from $25.9 million in Q2 2022, and down 9.17% quarter-over-quarter from $26.4 million in Q1 2023.
Cartesian Therapeutics (RNAC) Total Debt (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Total Debt for 9 consecutive years, with $24.0 million the latest figure, recorded in Q2 2023.
- In Q2 2023, Total Debt fell 7.32% year-over-year to $24.0 million; the TTM figure through Jun 2023 stood at $24.0 million (down 7.32% YoY), while the FY2022 annual figure was $26.3 million, up 2.45% from the prior year.
- Total Debt fell to $24.0 million in Q2 2023 per RNAC's latest filing, from $26.4 million in the prior quarter.
- Across five years, Total Debt topped out at $26.4 million in Q1 2023 and bottomed at $14.8 million in Q2 2020.
- Historically, Total Debt has averaged $23.3 million across 5 years, with a median of $24.9 million in 2020.
- Annual changes were most pronounced in 2020 — Total Debt plunged 31.16% — and 2021, when it soared 70.04%.
- Cartesian Therapeutics' Total Debt stood at $18.9 million in 2019, then soared by 31.15% to $24.8 million in 2020, then gained by 3.39% to $25.6 million in 2021, then climbed by 2.45% to $26.3 million in 2022, then fell by 8.53% to $24.0 million in 2023.
- Business Quant data shows RNAC's Total Debt at $24.0 million in Q2 2023, $26.4 million in Q1 2023, and $26.3 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.07 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.34 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Cartesian Therapeutics | 265.54 Mn | 265.54 Mn | - | 52.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 52.85 Mn |
| Jun 30, 2023 | 24.02 Mn |
| Mar 31, 2023 | 26.45 Mn |
| Dec 31, 2022 | 26.26 Mn |
| Sep 30, 2022 | 26.09 Mn |
| Jun 30, 2022 | 25.92 Mn |
| Mar 31, 2022 | 25.74 Mn |
| Dec 31, 2021 | 25.63 Mn |
| Sep 30, 2021 | 25.43 Mn |
| Jun 30, 2021 | 25.22 Mn |
| Mar 31, 2021 | 25.01 Mn |
| Dec 31, 2020 | 24.79 Mn |
| Sep 30, 2020 | 24.59 Mn |
| Jun 30, 2020 | 14.83 Mn |
| Mar 31, 2020 | 16.87 Mn |
| Dec 31, 2019 | 18.91 Mn |
| Sep 30, 2019 | 20.93 Mn |
| Jun 30, 2019 | 21.55 Mn |
| Mar 31, 2019 | 21.47 Mn |
| Dec 31, 2018 | 21.39 Mn |